본문 바로가기

business

Pipeline

SNK, autologous Immunotherapy

Clinical study in Korea : SNK01

  • Target disease : Combination therapy of non-small cell lung cancer + pembrolizumab
  • Trial No. : KCT0003463 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

Clinical study in the U.S. : SNK02

  • Target disease : Refractory cancer to conventional therapy.
  • Trial No. : KCT0003463 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

Clinical study in Mexico : SNK02

  • Target disease : Psoriasis (autoimmune disease)
  • Trial No. : NCT03894579 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II


Move to Top